Literature DB >> 3138208

Charged particle irradiation of chordoma and chondrosarcoma of the base of skull and cervical spine: the Lawrence Berkeley Laboratory experience.

A M Berson1, J R Castro, P Petti, T L Phillips, G E Gauger, P Gutin, J M Collier, S D Henderson, K Baken.   

Abstract

Forty-five consecutive patients with chordoma or chondrosarcoma at the base of skull or cervical spine were treated at the University of California Lawrence Berkeley Laboratory (UCLBL) and University of California School of Medicine, San Francisco (UCSF) between November 1977 and October 1986. All patients had undergone a subtotal surgical resection. Twenty-three patients were treated definitively with charged particles, 13 patients were treated with photons and particles, and 9 patients were treated for recurrent disease. Total doses ranged from 36 to 80 Gray equivalent (GyE). Thirty-three patients are alive with a minimum followup of 1 year. The actuarial survival and local control for all patients at 5 years is 62% and 59%, respectively. Patients treated for primary disease had a 78% actuarial local control rate at 2 years, whereas the rate for patients with recurrent disease was 33%. Patients with smaller visible tumor volumes (less than 20 cc) had a significantly better local control rate than patients with larger tumor volumes (80% vs 33% actuarial rate at 5 years). Patients with chondrosarcoma had the highest local control rate, as did patients treated with particles alone. Complications included 3 patients with unilateral visual loss, two patients who became blind, and 4 patients with radiation injury to the brainstem.

Entities:  

Mesh:

Year:  1988        PMID: 3138208     DOI: 10.1016/0360-3016(88)90295-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  11 in total

Review 1.  Current therapeutic options and novel molecular markers in skull base chordomas.

Authors:  Filippo Gagliardi; Nicola Boari; Paola Riva; Pietro Mortini
Journal:  Neurosurg Rev       Date:  2011-10-18       Impact factor: 3.042

2.  Chondrosarcomas of the petrous apex.

Authors:  R Charachon; B Gratacap; J P Lavieille
Journal:  Skull Base Surg       Date:  1992

Review 3.  Treatment planning with heavy ions.

Authors:  P Chauvel
Journal:  Radiat Environ Biophys       Date:  1995-03       Impact factor: 1.925

4.  Three-stage excision of recurrent cervical chondrosarcoma. A case report.

Authors:  A M Alpaslan; R E Acaroglu; M Kis
Journal:  Arch Orthop Trauma Surg       Date:  1993       Impact factor: 3.067

Review 5.  Adjuvant radiation therapy and chondroid chordoma subtype are associated with a lower tumor recurrence rate of cranial chordoma.

Authors:  Brian J Jian; Orin G Bloch; Isaac Yang; Seunggu J Han; Derick Aranda; Tarik Tihan; Andrew T Parsa
Journal:  J Neurooncol       Date:  2009-12-02       Impact factor: 4.130

Review 6.  Proton therapy in chordoma of the base of the skull: a systematic review.

Authors:  Maurizio Amichetti; Marco Cianchetti; Dante Amelio; Riccardo Maurizi Enrici; Giuseppe Minniti
Journal:  Neurosurg Rev       Date:  2009-03-25       Impact factor: 3.042

Review 7.  Review of skull base surgery approaches: with special reference to pediatric patients.

Authors:  J D Kennedy; S J Haines
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 8.  Results of heavy ion radiotherapy.

Authors:  J R Castro
Journal:  Radiat Environ Biophys       Date:  1995-03       Impact factor: 1.925

Review 9.  Proton therapy for brain tumours in the area of evidence-based medicine.

Authors:  Damien C Weber; Pei S Lim; Sebastien Tran; Marc Walser; Alessandra Bolsi; Ulrike Kliebsch; Jürgen Beer; Barbara Bachtiary; Tony Lomax; Alessia Pica
Journal:  Br J Radiol       Date:  2019-05-20       Impact factor: 3.039

10.  The radiation response of sarcomas by histologic subtypes: a review with special emphasis given to results achieved with razoxane.

Authors:  Walter Rhomberg
Journal:  Sarcoma       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.